Malignant melanoma, breast cancer and other cancers in patients with Parkinson's disease

International Journal of Cancer

Volumn 131, Issue 8, 2012, Pages 1904-1911

  Rugbjerg, Kathrine ^a   Friis, Søren ^a   Lassen, Christina Funch ^a   Ritz, Beate ^b   Olsen, Jørgen H ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cancer; Denmark; Parkinson's disease; population based cohort

Indexed keywords

ADULT; AGE; ARTICLE; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DENMARK; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; LARYNX CANCER; LIVER CANCER; LUNG CANCER; LYMPHATIC LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OVARY CANCER; PARKINSON DISEASE; PHARYNX CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SEX; SKIN CANCER; SMOKING; STOMACH CANCER; URINARY TRACT CANCER; UTERINE TUBE; UTERUS CANCER;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM GRADING; PARKINSON DISEASE; PROGNOSIS; RISK FACTORS;

EID: 84865325214     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27443     Document Type: Article

References (51)

1. Doshay LJ,. Problem situations in the treatment of paralysis agitans. J Am Med Assoc 1954; 156: 680-4.
2. Elbaz A, Peterson BJ, Bower JH, Yang P, Maraganore DM, McDonnell SK, Ahlskog JE, Rocca WA,. Risk of cancer after the diagnosis of Parkinson's disease: a historical cohort study. Mov Disord 2005; 20: 719-25. (Pubitemid 41051783)
3. D'Amelio M, Ragonese P, Morgante L, Epifanio A, Callari G, Salemi G, Savettieri G,. Tumor diagnosis preceding Parkinson's disease: a case-control study. Mov Disord 2004; 19: 807-11. (Pubitemid 39139592)
4. Driver JA, Kurth T, Buring JE, Gaziano JM, Logroscino G,. Prospective case-control study of nonfatal cancer preceding the diagnosis of Parkinson's disease. Cancer Causes Control 2007; 18: 705-11. (Pubitemid 46988238)
5. Elbaz A, Peterson BJ, Yang P, Van Gerpen JA, Bower JH, Maraganore DM, McDonnell SK, Ahlskog JE, Rocca WA,. Nonfatal cancer preceding Parkinson's disease: a case-control study. Epidemiology 2002; 13: 157-64. (Pubitemid 34160490)
6. Fois AF, Wotton CJ, Yeates D, Turner MR, Goldacre MJ,. Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson's disease: record linkage studies. J Neurol Neurosurg Psychiatry 2010; 81: 215-21.
7. Lo RY, Tanner CM, Van Den Eeden SK, Albers KB, Leimpeter AD, Nelson LM,. Comorbid cancer in Parkinson's disease. Mov Disord 2010; 25: 1809-17.
8. Olsen JH, Friis S, Frederiksen K,. Malignant melanoma and other types of cancer preceding Parkinson disease. Epidemiology 2006; 17: 582-7. (Pubitemid 44223068)
9. Becker C, Brobert GP, Johansson S, Jick SS, Meier CR,. Cancer risk in association with Parkinson disease: a population-based study. Parkinsonism Relat Disord 2010; 16: 186-90.
10. Driver JA, Logroscino G, Buring JE, Gaziano JM, Kurth T,. A prospective cohort study of cancer incidence following the diagnosis of Parkinson's disease. Cancer Epidemiol Biomarkers Prev 2007; 16: 1260-5. (Pubitemid 46984968)
11. Jansson B, Jankovic J,. Low cancer rates among patients with Parkinson's disease. Ann Neurol 1985; 17: 505-9. (Pubitemid 15019991)
12. Minami Y, Yamamoto R, Nishikouri M, Fukao A, Hisamichi S,. Mortality and cancer incidence in patients with Parkinson's disease. J Neurol 2000; 247: 429-34. (Pubitemid 30433556)
13. Moller H, Mellemkjaer L, McLaughlin JK, Olsen JH,. Occurrence of different cancers in patients with Parkinson's disease. BMJ 1995; 310: 1500-1.
14. Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Moller H,. Atypical cancer pattern in patients with Parkinson's disease. Br J Cancer 2005; 92: 201-5. (Pubitemid 40188456)
15. Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ,. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 2002; 52: 276-84. (Pubitemid 35001493)
16. Bertoni JM, Arlette JP, Fernandez HH, Fitzer-Attas C, Frei K, Hassan MN, Isaacson SH, Lew MF, Molho E, Ondo WG, Phillips TJ, Singer C, et al. Increased melanoma risk in Parkinson disease: a prospective clinicopathological study. Arch Neurol 2010; 67: 347-52.
17. Constantinescu R, Romer M, Kieburtz K,. Malignant melanoma in early Parkinson's disease: the DATATOP trial. Mov Disord 2007; 22: 720-2. (Pubitemid 46800147)
18. Inzelberg R, Rabey JM, Melamed E, Djaldetti R, Reches A, Badarny S, Hassin-Baer S, Cohen O, Trau H, Haron-Peretz J, Milo R, Schwartz M, et al. High prevalence of malignant melanoma in Israeli patients with Parkinson's disease. J Neural Transm 2011; 118: 1199-207.
19. Liu R, Gao X, Lu Y, Chen H,. Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology 2011; 76: 2002-9.
20. Bajaj A, Driver JA, Schernhammer ES,. Parkinson's disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control 2010; 21: 697-707.
21. Lynge E, Sandegaard JL, Rebolj M,. The Danish National Patient Register. Scand J Public Health 2011; 39 (7 Suppl): 30-3.
22. Gjerstorff ML,. The Danish Cancer Registry. Scand J Public Health 2011; 39 (7 Suppl): 42-5.
23. Breslow NE, Day NE,. Statistical methods in cancer research. Vol. II: The design and analysis of cohort studies. IARC Sci Publ 1987; 82: 100-406.
24. Secretan B, Straif K, Baan R, Grosse Y, El GF, Bouvard V, Brahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V,. A review of human carcinogens, Part E: Tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol 2009; 10: 1033-4.
25. Moller S, Jensen MB, Ejlertsen B, Bjerre KD, Larsen M, Hansen HB, Christiansen P, Mouridsen HT,. The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol 2008; 47: 506-24. (Pubitemid 351878431)
26. Osler M, Prescott E, Gottschau A, Bjerg A, Hein HO, Sjol A, Schnohr P,. Trends in smoking prevalence in Danish adults, 1964-1994. The influence of gender, age, and education. Scand J Soc Med 1998; 26: 293-8.
27. Haaxma CA, Bloem BR, Borm GF, Oyen WJ, Leenders KL, Eshuis S, Booij J, Dluzen DE, Horstink MW,. Gender differences in Parkinson's disease. J Neurol Neurosurg Psychiatry 2007; 78: 819-24. (Pubitemid 47204585)
28. Olsen JH, Tangerud K, Wermuth L, Frederiksen K, Friis S,. Treatment with levodopa and risk for malignant melanoma. Mov Disord 2007; 22: 1252-7. (Pubitemid 47325031)
29. Herrero HE,. Pigmentation genes link Parkinson's disease to melanoma, opening a window on both etiologies. Med Hypotheses 2009; 72: 280-4.
30. Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A,. Genetic determinants of hair color and Parkinson's disease risk. Ann Neurol 2009; 65: 76-82.
31. Han J, Kraft P, Colditz GA, Wong J, Hunter DJ,. Melanocortin 1 receptor variants and skin cancer risk. Int J Cancer 2006; 119: 1976-84. (Pubitemid 44356860)
32. Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A,. Family history of melanoma and Parkinson disease risk. Neurology 2009; 73: 1286-91.
33. Olsen JH, Jorgensen TL, Rugbjerg K, Friis S,. Parkinson disease and malignant melanoma in first-degree relatives of patients with early-onset melanoma. Epidemiology 2011; 22: 109-12.
34. Anderson WF, Pfeiffer RM, Tucker MA, Rosenberg PS,. Divergent cancer pathways for early-onset and late-onset cutaneous malignant melanoma. Cancer 2009; 115: 4176-85.
35. Paisan-Ruiz C, Houlden H,. Common pathogenic pathways in melanoma and Parkinson disease. Neurology 2010; 75: 1653-5.
36. Jimbow K, Salopek TG, Dixon WT, Searles GE, Yamada K,. The epidermal melanin unit in the pathophysiology of malignant melanoma. Am J Dermatopathol 1991; 13: 179-88.
37. Chang YM, Barrett JH, Bishop DT, Armstrong BK, Bataille V, Bergman W, Berwick M, Bracci PM, Elwood JM, Ernstoff MS, Gallagher RP, Green AC, et al. Sun exposure and melanoma risk at different latitudes: a pooled analysis of 5700 cases and 7216 controls. Int J Epidemiol 2009; 38: 814-30.
38. Henderson BE, Feigelson HS,. Hormonal carcinogenesis. Carcinogenesis 2000; 21: 427-33. (Pubitemid 30137927)
39. Bourque M, Dluzen DE, Di PT,. Neuroprotective actions of sex steroids in Parkinson's disease. Front Neuroendocrinol 2009; 30: 142-57.
40. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, Nelson LM,. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003; 157: 1015-22. (Pubitemid 36628805)
41. Shiloh Y, Rotman G,. Ataxia-telangiectasia and the ATM gene: linking neurodegeneration, immunodeficiency, and cancer to cell cycle checkpoints. J Clin Immunol 1996; 16: 254-60. (Pubitemid 26338198)
42. Eilam R, Peter Y, Elson A, Rotman G, Shiloh Y, Groner Y, Segal M,. Selective loss of dopaminergic nigro-striatal neurons in brains of Atm-deficient mice. Proc Natl Acad Sci USA 1998; 95: 12653-6.
43. Olsen JH, Hahnemann JM, Borresen-Dale AL, Tretli S, Kleinerman R, Sankila R, Hammarstrom L, Robsahm TE, Kaariainen H, Bregard A, Brondum-Nielsen K, Yuen J, et al. Breast and other cancers in 1445 blood relatives of 75 Nordic patients with ataxia telangiectasia. Br J Cancer 2005; 93: 260-5. (Pubitemid 41133213)
44. Swift M, Morrell D, Massey RB, Chase CL,. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 1991; 325: 1831-6.
45. Thompson D, Duedal S, Kirner J, McGuffog L, Last J, Reiman A, Byrd P, Taylor M, Easton DF,. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst 2005; 97: 813-22. (Pubitemid 40909124)
46. Cesari R, Martin ES, Calin GA, Pentimalli F, Bichi R, McAdams H, Trapasso F, Drusco A, Shimizu M, Masciullo V, D'Andrilli G, Scambia G, et al. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci USA 2003; 100: 5956-61. (Pubitemid 36581860)
47. Kim RH, Mak TW,. Tumours and tremors: how PTEN regulation underlies both. Br J Cancer 2006; 94: 620-4. (Pubitemid 43361890)
48. Nagai MA, Da RN, Neto MM, de FJ, Sr, Brentani MM, Hirata R, Jr, Neves EJ,. Gene expression profiles in breast tumors regarding the presence or absence of estrogen and progesterone receptors. Int J Cancer 2004; 111: 892-9. (Pubitemid 39096238)
49. Gasser T,. Genetics of Parkinson's disease. Curr Opin Neurol 2005; 18: 363-9. (Pubitemid 41104797)
50. Chen H, Huang X, Guo X, Mailman RB, Park Y, Kamel F, Umbach DM, Xu Q, Hollenbeck A, Schatzkin A, Blair A,. Smoking duration, intensity, and risk of Parkinson disease. Neurology 2010; 74: 878-84.
51. Inzelberg R, Jankovic J,. Are Parkinson disease patients protected from some but not all cancers? Neurology 2007; 69: 1542-50. (Pubitemid 47537862)